The 36-month beta value for APGE is at 2.79. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 6 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for APGE is 36.29M, and currently, shorts hold a 22.81% of that float. The average trading volume for APGE on September 23, 2024 was 440.08K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
APGE) stock’s latest price update
Apogee Therapeutics Inc. (NASDAQ: APGE)’s stock price has gone rise by 10.35 in comparison to its previous close of 52.95, however, the company has experienced a 13.72% increase in its stock price over the last five trading days. globenewswire.com reported 2024-09-12 that SAN FRANCISCO and WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) — Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced that members of management, will participate in a fireside chat at the Stifel 2024 Immunology and Inflammation Summit on Wednesday, September 18, 2024 at 12:30 p.m. E.T. / 9:30 a.m. P.T.
APGE’s Market Performance
APGE’s stock has risen by 13.72% in the past week, with a monthly rise of 20.85% and a quarterly rise of 53.76%. The volatility ratio for the week is 6.89% while the volatility levels for the last 30 days are 5.50% for Apogee Therapeutics Inc. The simple moving average for the past 20 days is 18.32% for APGE’s stock, with a 32.21% simple moving average for the past 200 days.
Analysts’ Opinion of APGE
Many brokerage firms have already submitted their reports for APGE stocks, with BofA Securities repeating the rating for APGE by listing it as a “Buy.” The predicted price for APGE in the upcoming period, according to BofA Securities is $80 based on the research report published on May 10, 2024 of the current year 2024.
BTIG Research, on the other hand, stated in their research note that they expect to see APGE reach a price target of $43. The rating they have provided for APGE stocks is “Buy” according to the report published on December 20th, 2023.
Wedbush gave a rating of “Outperform” to APGE, setting the target price at $40 in the report published on August 08th of the previous year.
APGE Trading at 22.56% from the 50-Day Moving Average
After a stumble in the market that brought APGE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -19.17% of loss for the given period.
Volatility was left at 5.50%, however, over the last 30 days, the volatility rate increased by 6.89%, as shares surge +22.19% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +27.22% upper at present.
During the last 5 trading sessions, APGE rose by +13.72%, which changed the moving average for the period of 200-days by +187.83% in comparison to the 20-day moving average, which settled at $49.91. In addition, Apogee Therapeutics Inc. saw 109.13% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at APGE starting from Dambkowski Carl, who sale 6,665 shares at the price of $47.56 back on Sep 04 ’24. After this action, Dambkowski Carl now owns 280,793 shares of Apogee Therapeutics Inc., valued at $316,969 using the latest closing price.
HENDERSON MICHAEL THOMAS, the Chief Executive Officer of Apogee Therapeutics Inc., sale 40,000 shares at $47.62 during a trade that took place back on Sep 04 ’24, which means that HENDERSON MICHAEL THOMAS is holding 1,394,487 shares at $1,904,841 based on the most recent closing price.
Stock Fundamentals for APGE
The total capital return value is set at -0.19. Equity return is now at value -26.73, with -25.44 for asset returns.
Based on Apogee Therapeutics Inc. (APGE), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -27.08.
Currently, EBITDA for the company is -93.0 million with net debt to EBITDA at 2.16. The liquidity ratio also appears to be rather interesting for investors as it stands at 27.70.
Conclusion
In conclusion, Apogee Therapeutics Inc. (APGE) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
